Extrapulmonary Neuroendocrine Carcinoma — An Interview with Dr Jonathan Strosberg on Current and Future Management (Companion Faculty Lecture)
Research To Practice | Oncology Videos
00:00
Use of Targeted Therapy Based on NGS Findings
Strosberg notes occasional benefit from targeted agents (e.g., BRAF) when actionable mutations are identified via NGS.
Play episode from 13:19
Transcript
